February 21, 2017
‘Fasting-mimicking’ diet said to reduce risk factors for aging
Following a diet that mimics fasting may reduce risk factors for disease in generally healthy people, according to a small study.
Pharmaceuticals, Biotechnology and Life Sciences
Category: Europe
February 21, 2017
Sobi, Valeant sign new agreement for UCDs drug distribution
Swedish Orphan Biovitrum (Sobi) has entered into a 3-year agreement with Ireland’s Valeant Pharmaceuticals for the distribution of Ammonul injection, an acute Urea Cycle Disorders (UCDs) drug, in Europe, the Middle East and North Africa.
February 21, 2017
Nicox presents positive preclinical results for its eye drug
Nicox, the international ophthalmic R&D company has presented preclinical results from its novel nitric oxide (NO) donating compound, NCX 667 at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting, held from February 16-19, 2017, in Florence, Italy.
February 21, 2017
Neovacs’s lupus and dermatomyositis vaccine to sell in China
Neovacs has signed with BioSense Global a commercial license option agreement for its IFNalpha Kinoid vaccine to treat lupus and dermatomyositis in China, worth up to €65 million in upfront and milestone payments, not including double-digit sales royalties.
February 21, 2017
Apitope’s multiple sclerosis drug brings brain lesions down
Apitope’s ATX-MS-1467 has reduced the number and volume of brain lesions with a promising safety profile, the company said about results of a test.
February 20, 2017
Russian Government drive to increase domestic manufacturing fuelling growth at CPhI Russia
The partnerships and deals struck at CPhI Russia have helped establish Russia at the forefront of pharmerging markets and it is expected to reach a value of $31.2 billion by 2019.
February 20, 2017
Faron recruits first patent for Traumakine, a Multi-Organ Failure drug
Faron Pharmaceuticals has recruited first patient in the Phase II INFORAAA clinical trial of Traumakine for the treatment of Multi-Organ Failure (MOF) and mortality prevention of surgically operated Ruptured Abdominal Aorta Aneurysm (RAAA) patients.
February 20, 2017
Mereo BioPharma’s rare bone disease drug to develop sooner
Mereo BioPharma’s bone disease drug BPS-804 has been accepted to participate in the European Medicines Agency’s (EMA) Adaptive Pathways programme.
February 20, 2017
TerSera buys commercial rights for AstraZeneca’s cancer drug in North America
AstraZeneca has entered into an agreement with TerSera Therapeutics for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada, an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benign gynaecological disorders.
February 17, 2017
Vote of confidence for life-science sector, Arix rasies £100M in initial public offering
London-listed healthcare company Arix Bioscience said on Friday it raised £100 million in its Initial Public Offering, with total market capitalisation at Admission to be £187 million.